This article is more than 5 years old. Information may no longer be current.
Vision improves in anti-VEGF veterans enrolled in HiPED study
LAS VEGAS — Anti-VEGF veterans with wet age-related macular degeneration and pigment epithelial detachments achieved better visual acuity after receiving 2-mg monthly injections of ranibizumab, according to a presenter here.
Anne Fung, MD, presented 1-year results of the HiPED (High dose Lucentis for persistent pigment epithelial detachments in age-related macular degeneration) study at the American Society of Retina Specialists meeting.
Anne Fung
Forty patients gained an average of more than five letters after 1 year of treatment in the 2-year prospective, randomized, controlled, open-label, multicenter, investigator-sponsored study. The average patient age was 75 years, and the mean number of previous injections was 22.
“Looking at visual acuity from baseline through month 12, even though these patients had had consecutive injections previously, there was a continued, steady improvement in the visual acuity to an average gain of over five letters at the first year,” Fung said.
Neovascular AMD with pigment epithelial detachment is particularly challenging to treat, Fung said.
“[Pigment epithelial detachments] are the last compartment of fluid to resolve and are predictors of worse vision outcomes,” she said.
The study is limited by small sample size and the lack of indocyanine green study at baseline, Fung said.
-
Disclosure: Fung is a consultant for or receives research funding from Genentech, Santen, ThromboGenics, Alcon and Sequenom.